Icon
+91 94997 68112
Login Register

DEFENCATH - (3000UNITS/3ML;40.5MG/3ML, 5000UNITS/5ML;67.5MG/5ML)

HEPARIN SODIUM; TAUROLIDINE None
3000UNITS/3ML;40.5MG/3ML, 5000UNITS/5ML;67.5MG/5ML
Less Than $1000 mn
None None
None None
None None
DEFENCATH is a combination of taurolidine, a thiadiazinane antimicrobial, and heparin, an anti-coagulant, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis (HD) through a central venous catheter (CVC). This drug is indicated for use in a limited and specific population of patients.
Yes
DEFENCATH Patent 1 Patent 2 Patent 3 Patent 4
*** *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.